Paid Clinical Trials Chattanooga
Discover 128 paid clinical trials in Chattanooga, Tennessee. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
BHV-7000Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
Sponsor:
Biohaven Therapeutics Ltd.
Location:
Code:
NCT06309966
Conditions
Focal Epilepsy
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
BHV-7000
Placebo
ONC-392 & Anti-PD-1Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
Sponsor:
OncoC4, Inc.
Location:
Code:
NCT04140526
Conditions
Non Small Cell Lung Cancer
Advanced Solid Tumor
Metastatic Melanoma
Metastatic Head and Neck Carcinoma
Metastatic Renal Cell Carcinoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
ONC-392
Pembrolizumab
Docetaxel
CIN-103Study of the Research Medicine CIN-103 in Adults with Irritable Bowel Syndrome with Predominant Diarrhea (IBS-D).
Sponsor:
CinPhloro Pharma, LLC
Location:
Code:
NCT06153420
Conditions
Irritable Bowel Syndrome with Diarrhea
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
CIN-103
Placebo
Budesonide, Glycopyrronium, FormoterolA Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
Sponsor:
AstraZeneca
Location:
Code:
NCT06283966
Conditions
COPD (Chronic Obstructive Pulmonary Disease)
Eligibility Criteria
Sex: All
Age: 40 - 70+
Healthy Volunteers: Not accepted
Interventions
BGF MDI 320/14.4/9.6 μg
GFF MDI 14.4/9.6 μg
CamizestrantAn Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
Sponsor:
AstraZeneca
Location:
Code:
NCT05952557
Conditions
Breast Cancer, Early Breast Cancer
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Camizestrant
Tamoxifen
Anastrozole
Letrozole
Exemestane
SeladelparIntended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC)
Sponsor:
Gilead Sciences
Location:
Code:
NCT06060665
Conditions
Primary Biliary Cholangitis
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Seladelpar 10 mg
Placebo
Baxdrostat & DapagliflozinA Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.
Sponsor:
AstraZeneca
Location:
Code:
NCT06268873
Conditions
Chronic Kidney Disease and Hypertension
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Baxdrostat/dapagliflozin
Dapagliflozin in combination with placebo
DupilumabA Trial to Learn if Dupilumab is Safe for and Helps Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis
Sponsor:
Regeneron Pharmaceuticals
Location:
Code:
NCT05831176
Conditions
Eosinophilic Gastritis
Eosinophilic Duodenitis
Eosinophilic Gastrointestinal Disease
Eligibility Criteria
Sex: All
Age: 12+
Healthy Volunteers: Not accepted
Interventions
Dupilumab Dose 1
Dupilumab Dose 2
Matching Placebo
Robotic vs. OpenA Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer
Sponsor:
GOG Foundation
Location:
Code:
NCT04831580
Conditions
Cervical Cancer
Eligibility Criteria
Sex: Female
Age: 18+
Healthy Volunteers: Not accepted
Interventions
da Vinci
open surgery
Glofitamab & Polatuzumab VedotinAn Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma
Sponsor:
Hoffmann-La Roche
Location:
Code:
NCT06047080
Conditions
Large B-Cell Lymphoma
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Glofitamab
Polatuzumab vedotin
Rituximab
Cyclophosphamide
Doxorubicin